| Literature DB >> 27825117 |
Xia Lingzi1,2, Yin Zhihua1,2, Li Xuelian1,2, Ren Yangwu1,2, Zhang Haibo3, Zhao Yuxia4, Zhou Baosen1,2.
Abstract
To investigate the prognostic effect of microRNA single nucleotide polymorphisms (SNP) on non-small cell lung cancer (NSCLC) patients, 658 female participants from northeast China were enrolled in our prospective cohort study and followed up from 2010 to 2015. C-containing genotypes of miR-149 rs2292832 were associated with better overall survival (OS). The joint effect of miR-149 and miR-196a2 and the joint effect of miR-149 and miR-608 were also observed in our study. To verify the function of miR-149 rs2292832, A549 cell lines were stably transfected with lenti-virus containing miR-149-C vector, miR-149-T vector and empty vector. Cells containing C allele assumed a higher expression level of miR-149, a decrease in cell growth and the sensitivity to anticancer drug when compared with cells containing T allele. The role of miR-149 playing in cancer prognosis may function through DNA topoisomerases 1 (TOP1) pathway, according to the results from luciferase reporter assays. In conclusion, miR-149 C allele may be a prognostic biomarker for better NSCLC OS.Entities:
Keywords: Chinese; SNP; lung cancer; miRNA; prognosis
Mesh:
Substances:
Year: 2016 PMID: 27825117 PMCID: PMC5347756 DOI: 10.18632/oncotarget.13072
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
The baseline characteristics of the non-small cell lung cancer patients
| Characteristics | cases (584) | % | Deaths | % | P-value | MST (months) | Log-rank P-value |
|---|---|---|---|---|---|---|---|
| Age(yr) | 0.579 | 0.856 | |||||
| ≤60 | 252 | 43.1 | 209 | 82.9 | 25.54 | ||
| >60 | 332 | 56.9 | 281 | 84.6 | 25.86 | ||
| Tobaccon exposure | |||||||
| Smoker | 326 | 55.8 | 273 | 83.8 | 0.613 | 22.90 | 0.146 |
| Non-smoker | 258 | 44.2 | 220 | 85.2 | 18.53 | ||
| Histological type | 0.406 | <0.001 | |||||
| AD | 317 | 54.3 | 260 | 82.0 | 22.79 | ||
| SQU | 230 | 39.4 | 201 | 87.4 | 25.01 | ||
| others | 37 | 6.3 | 29 | 78.4 | 34.80 | ||
| Clinical stage | <0.001 | <0.001 | |||||
| I | 132 | 22.6 | 94 | 71.2 | 41.56 | ||
| II | 65 | 11.1 | 51 | 78.5 | 27.43 | ||
| III | 309 | 52.9 | 275 | 89.0 | 18.86 | ||
| IV | 78 | 13.4 | 70 | 89.7 | 23.67 | ||
| Chemotherapy | 0.225 | <0.001 | |||||
| no | 55 | 9.4 | 43 | 78.2 | 15.15 | ||
| yes | 529 | 90.6 | 447 | 84.5 | 27.67 | ||
| Surgery | 0.218 | 0.005 | |||||
| no | 200 | 34.2 | 173 | 86.5 | 22.48 | ||
| yes | 384 | 65.8 | 317 | 82.6 | 27.40 | ||
*AD: adenocarcinoma, SQU:squamous carcinoma, others: large cell carcinoma or mixed types, MST: median survival time.
The association between the five SNPs and OS
| SNP Genotypes | cases | MST | Log-rank P-value | Crude HR | 95% CI (P-value) | aHR | 95%CI(P-value) |
|---|---|---|---|---|---|---|---|
| mir-149 rs2292832 | |||||||
| TT | 419 | 24.08 | 0.004 | 1 | 1 | ||
| CT | 120 | 28.50 | 0.781 | 0.626-0.976(0.029) | 0.782 | 0.626-0.976(0.030) | |
| CC | 45 | 32.59 | 0.608 | 0.425-0.870(0.006) | 0.607 | 0.425-0.869(0.006) | |
| TT | 419 | 24.08 | 0.002 | 1 | 1 | ||
| CC+CT | 165 | 29.62 | 0.730 | 0.598-0.892(0.002) | 0.739 | 0.605-0.903(0.003) | |
| CT+TT | 539 | 25.09 | 0.015 | 1 | 1 | ||
| CC | 45 | 32.59 | 0.647 | 0.454-0.922(0.016) | 0.644 | 0.452-0.919(0.015) | |
| mir-146a rs2910164 | |||||||
| CC | 189 | 25.68 | 0.983 | 1 | 1 | ||
| CG | 302 | 25.59 | 0.986 | 0.807-1.204(0.886) | 0.999 | 0.818-1.221(0.995) | |
| GG | 93 | 25.44 | 1.005 | 0.766-1.319(0.969) | 0.967 | 0.737-1.269(0.808) | |
| mir-196a2 rs11614913 | |||||||
| TT | 145 | 24.21 | 0.414 | 1 | 1 | ||
| CT | 319 | 26.07 | 0.916 | 0.738-1.136(0.424) | 0.978 | 0.788-1.214(0.842) | |
| CC | 120 | 27.17 | 0.833 | 0.635-1.093(0.187) | 0.854 | 0.651-1.121(0.255) | |
| mir-608 rs4919510 | |||||||
| GG | 154 | 24.79 | 0.803 | 1 | 1 | ||
| CG | 308 | 23.53 | 1.070 | 0.836-1.370(0.590) | 0.976 | 0.762-1.251(0.849) | |
| CC | 122 | 25.06 | 0.996 | 0.735-1.350(0.980) | 1.015 | 0.749-1.375(0.925) | |
| mir-423 rs6505162 | |||||||
| CC | 386 | 24.27 | 0.874 | 1 | 1 | ||
| AC | 181 | 24.22 | 1.010 | 0.805-1.269(0.929) | 1.017 | 0.809-1.277(0.886) | |
| AA | 17 | 25.10 | 0.853 | 0.453-1.606(0.622) | 0.953 | 0.506-1.796(0.881) | |
*MST: median survival time, aHR: HR adjusted by histological type, clinical stage, receipt of chemotherapy or surgery.
Figure 1Survival curves for patients with different genotypes of miR-149
Stratified analyses of the association between the five SNPs and OS
| SNPs subgroup | cases | Model | aHR | 95%CI (P-value) |
|---|---|---|---|---|
| mir-149 rs2292832 | ||||
| AGE>60 | 332 | CC vs TT | 0.494 | 0.294-0.830(0.008) |
| CC+CT vs TT | 0.693 | 0.509-0.943(0.020) | ||
| CC vs CT+TT | 0.519 | 0.311-0.866(0.012) | ||
| AGE≤60 | 252 | CT vs TT | 0.749 | 0.560-1.001(0.051) |
| CC+CT vs TT | 0.758 | 0.582-0.987(0.040) | ||
| Non-smoker | 258 | CC vs TT | 0.376 | 0.205-0.691(0.002) |
| CT vs TT | 0.537 | 0.376-0.767(0.001) | ||
| Smoker | 326 | CC vs TT | 0.619 | 0.392-0.976(0.039) |
| SQU | 230 | CC vs TT | 0.535 | 0.317-0.901(0.019) |
| CT vs TT | 0.651 | 0.444-0.955(0.028) | ||
| CC+CT vs TT | 0.608 | 0.437-0.847(0.003) | ||
| CC vs CT+TT | 0.598 | 0.357-1.000(0.050) | ||
| I/II/III | 509 | CC vs TT | 0.625 | 0.424-0.921(0.017) |
| CT vs TT | 0.795 | 0.625-1.011(0.062) | ||
| CC+CT vs TT | 0.746 | 0.600-0.926(0.008) | ||
| CC vs CT+TT | 0.662 | 0.451-0.972(0.035) | ||
| Chemotherapy | 529 | CC vs TT | 0.622 | 0.432-0.895(0.010) |
| CT vs TT | 0.735 | 0.583-0.927(0.009) | ||
| CC vs CT+TT | 0.673 | 0.470-0.965(0.031) | ||
| CC+CT vs TT | 0.702 | 0.570-0.864(0.001) | ||
| Surgery | 384 | CT vs TT | 0.677 | 0.509-0.901(0.008) |
| CC vs TT | 0.540 | 0.348-0.839(0.006) | ||
| CC+CT vs TT | 0.635 | 0.492-0.819(<0.001) | ||
| CC vs CT+TT | 0.598 | 0.387-0.923(0.020) | ||
| mir-196a2 rs11614913 | ||||
| SQU | 230 | CC vs TT | 0.608 | 0.384-0.963(0.034) |
| CC vs CT+TT | 0.679 | 0.463-0.996(0.047) | ||
| mir-608 rs4919510 | ||||
| Chemotherapy | 529 | CC vs GG | 1.277 | 1.036-1.535(0.028) |
| Surgery | 384 | CC vs GG | 1.411 | 1.066-1.814(0.040) |
| CC+CG vs GG | 1.359 | 1.056-1.762(0.013) | ||
*SQU: squamous carcinoma, aHR: HR adjusted by histological type, clinical stage and therapeutic strategy.
Figure 2Survival curves for I/II/III patients with different genotypes of miR-149
The joint effect of the miRNA SNPs on OS
| Strata | miRNAs | Model | Cases | HR | 95%CI | P |
|---|---|---|---|---|---|---|
| SQU | miR-149, miR-196a2 | |||||
| 0 | 42 | 1.00 | ||||
| 1 | 98 | 0.886 | 0.594-1.323 | 0.555 | ||
| 2 | 62 | 0.614 | 0.392-0.961 | 0.033 | ||
| 3+4 | 28 | 0.484 | 0.270-0.866 | 0.015 | ||
| Chemotherapy | miR-149, miR-608 | |||||
| 0 | 75 | 1.00 | ||||
| 1 | 229 | 1.097 | 0.787-1.529 | 0.584 | ||
| 2 | 168 | 1.029 | 0.733-1.445 | 0.867 | ||
| 3+4 | 57 | 0.572 | 0.367-0.893 | 0.014 | ||
| Surgery | miR-149, miR-608 | |||||
| 0 | 57 | 1.00 | ||||
| 1 | 164 | 1.241 | 0.857-1.798 | 0.253 | ||
| 2 | 120 | 1.139 | 0.774-1.676 | 0.509 | ||
| 3+4 | 43 | 0.587 | 0.356-0.968 | 0.037 |
0:TT of miR-149 and miR-196a2; 1:CT of miR-149 and TT of miR-196a2, or TT of miR-149 and CT of miR-196a2; 2: CT of miR-149 and miR-196a2, or CC of miR-149 and TT of miR-196a2, or TT of miR-149 and CC of miR-196a2; 3: CT of miR-149 and CC of miR-196a2, or CC of miR-149 and CT of miR-196a2; 4: CC of miR-149 and miR-196a2.
0:TT of miR-149 and CC of miR-608; 1: TT of miR-149 and CG of miR-608, or CT of miR-149 and CC of miR-608; 2: TT of miR-149 and GG of miR-608, or CC of miR-149 and CC of miR-608, or CT of miR-149 and CG of miR-608; 3: CT of miR-149 and GG of miR-608, or CC of miR-149 and CG of miR-608; 4: CC of miR-149 and GG of miR-608
SQU:squamous cell carcinoma.
Figure 3Effect of miR-149 rs2292832 on cell proliferation
Figure 4Effect of miR-149 rs2292832 on cell cycle
Figure 5The results of luciferase reporter assay
Figure 6The western blotting results
Figure 7Resutls for drug sensitivity assays